Journal
HEPATOLOGY INTERNATIONAL
Volume 10, Issue 5, Pages 702-726Publisher
SPRINGER
DOI: 10.1007/s12072-016-9717-6
Keywords
APASL; DAAs; HCV; Interferon-free; Turkey
Categories
Funding
- Bayer Co
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Otsuka
- Astellas
- Gilead Sciences
- Chugai
- Mitsubishi Tanabe
- Kyorin
- Merck Sharp Dohme
- Dainippon Sumitomo
- Vertex Pharmaceuticals
- Takeda
- Zeria
- Chugai Pharmaceutical
- MSD
- Tanabe-Mitsubishi
- Daiichi-Sankyo
- Abbvie
- Roche
- Abbott
- BMS
- Gilead
- Kowa Souku
- Sysmex
- Chugai Pharmaceutical Co
- GlaxoSmithKline
- Ajinomoto-Seiyaku
- Bayer
- Given Imaging
- Mitsubishi Tanabe Pharm
- Taiho Yakuhin
- Dainippon Sumitomo Pharm
- Igaku-Seibutsugaku Institute
Ask authors/readers for more resources
The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the APASL consensus statements and recommendation on management of hepatitis C in March, 2015, in order to revise APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available